-
Zdravljenje diseminiranega plazmocitoma z zdravilom bortezomib = Treatment of multiple myeloma with bortezomibKodre, Veronika ; Černelč, PeterBackground In this retrospective study we evaluated effectiveness and safety of bortezomib, comparing our results with already published clinical studies. Methods Patients received bortezomib as part ... of everyday clinical practice andin the range of approved indications. We evaluated bortezomib effectivenessin 66 patients according to modified SWOG criteria and treatment responsiveness (CR, VGPR, PR, MR) or unresponsiveness (SD, PD). Treatment responsiveness was compared according to high risk (beta-2 microglobulin >= 5,5 mg/L) or standard risk (beta-2 mikroglobulin < 5.5 mg/L), patient's age (>65 ali < 65 let), number of previous treatments (1 ali > 1) and previous treatment with thalidomid. Side effects and reasons for early treatment discontinuation were also evaluated. Results Patients received 1-7 previous treatments (median 1.5). Treatment responsiveness was observed in 80.3% patients (1.5% CR, 45.5 % VGPR, 21.2% PR and 12.1% MR). No statistical significant influence was observed according to: high risk (p = 0.178), age above 65 years (p = 0.756), > 1 previous treatment (p = 0.419) or previous treatment with thalidomid (p = 0.475). Side effects of bortezomib treatment were: anemia (40.9%), peripheral neuropathy grade 3 or more (28.7%), infections (21.2%), herpes zooster (12.1%), neutropenia (10.6%), trombocitopenia (9%) and gastro-intestinal problems (7.5%). Early discontinuation was observed due to: peripheral neuropathy (28.7%), other serious side effects (6%), bortezomib uneffectiveness (19.7%) or planned autologous transplant (15.1%). Conclusions Bortezomib (Velcade) is effective and safe treatment also for patients with multiple myeloma that developed resistance to previous treatments or belong to high risk patient group.Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 77, supl. 1, apr. 2008, str. I-87-I-92)Vrsta gradiva - prispevek na konferenciLeto - 2008Jezik - slovenskiCOBISS.SI-ID - 24129753
Avtor
Kodre, Veronika |
Černelč, Peter
Teme
Multiple Myeloma |
Drug Therapy |
Immunoglobulins |
Beta 2-Microglobulin |
Bence Jones Protein |
Treatment Outcome |
Beta 2-mikroglobulini |
Imunoglobulini |
Bence Jonesova beljakovina |
Zdravljenje, izid |
Multipli mielom |
hematologija |
plazmocitom |
zdravljenje
![loading ... loading ...](themes/default/img/ajax-loading.gif)
vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 77, supl. 1, apr. 2008, str. I-87-I-92)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Kodre, Veronika | ![]() |
Černelč, Peter | 07012 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi